Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.52 |
| ▸ | CCR9 | P51686 | 1/20 | 0.46 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137692 | 0.87 | CCR2 (0.51) | CCR2 | |
| SCHEMBL1094119 | 0.84 | CCR2 (0.49) | CCR2 | |
| SCHEMBL13146500 | 0.77 | CCR2 (0.59) | CCR2 | |
| SCHEMBL3098575 | 0.76 | CCR2 (0.66) | CCR2PGAM1 | |
| SCHEMBL9931082 | 0.76 | CCR2 (0.67) | CCR2 | |
| SCHEMBL1037893 | 0.75 | CCR2 (0.46) | CCR2PGAM1 | |
| SCHEMBL1094291 | 0.75 | CCR9 (0.59) | CCR9 | |
| SCHEMBL1034833 | 0.74 | CYP2C9 (0.45) | CCR2CCR9 | |
| SCHEMBL1035735 | 0.73 | CCR2 (0.47) | CCR2CCR9PGAM1 | |
| SCHEMBL13146618 | 0.73 | CCR2 (0.58) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | claimed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | claimed |
| EP-2046762-B1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX INC (US) | 2011-02-16 | — | — | EP | claimed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | claimed |
| EP-2046762-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | ChemoCentryx Inc (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | claimed |
| WO-2008010934-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008010934-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | CCR2 2/4885CCR9 1/4885PGAM1 3774/4885 |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | CCR2 2/4885CCR9 1/4885PGAM1 3774/4885 |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | CCR2 2/4885CCR9 1/4885PGAM1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.